January 07, 2008 09:15 ET

Improving Medication Safety: Independent 18 Month Study of ValiMed™ Medication Validation System by CDEX Published in American Journal of Health-System Pharmacists

ValiMed™ Detected Five Potentially Serious Medication Errors While Consistently Validating the Correct Medication Solutions During an 18 Month Study at a Major University Hospital

TUCSON, AZ--(Marketwire - January 7, 2008) - CDEX, Inc. (OTCBB: CEXI) announces publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. "During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided," the report stated. "[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard." (Am J Health-Syst Pharm--Vol 65, pp 49-54, Jan 1, 2008, "Enhanced Photoemission Spectroscopy for Verification of High-Risk IV Medications.")

"Errors in compounding these types of medications are rare. However, when they occur they can have a significant negative impact on patients and staff," said one of the authors, Jim Stevenson, Associate Dean of Clinical Sciences at the University of Michigan College of Pharmacy and Director of Pharmacy Services at the University's Health System. "Our goal is to have zero tolerance for errors. We know from having ValiMed™ in place we've deterred five potentially serious errors that might have happened. I really believe having technology like this needs to be the standard around the country." (Stevenson's statements are drawn from a University of Michigan press release and are quoted with permission (see

"This peer reviewed Study was a comprehensive analysis of our patented technologies and first generation ValiMed units," said Malcolm Philips, CDEX CEO. "Jim Stevenson and his Staff at the University of Michigan Health System are among the best and most forward-thinking health care organizations in the nation, with a zero tolerance policy for medication errors. They have stepped forward to tackle a significant problem facing the entire medical community and we look forward to working with them and other top rated national and international hospitals in our collective efforts to provide the best standard of care for patients."

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to its expected CDEX Library signature and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

About CDEX, Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit and or contact Malcolm Philips ( or Stuart Poteet ( at 520.745.5172 X 210 or 202.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Sec. There is no obligation to publicly update any forward-looking statements.

Contact Information